Biologic Development Image

Scientific Advisory Board

Steven Carr, PhD

Steven Carr is senior director of proteomics at the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine. Dr. Carr and his group of staff scientists and postdoctoral fellows collaborate with scientists throughout the Broad Institute community (comprised of MIT, Harvard University Faculty of Arts and Sciences, Harvard Medical School, and the 17 Harvard-affiliated hospitals) to apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine. Research in his laboratory focuses on developing and applying new technologies to quantify proteins and their modifications and interaction partners in tissues, cells, and biofluids with high sensitivity and specificity; improving informatics for peptide and protein assignment using mass spectrometry (MS) data; and integration of MS-derived data with genomic data to understand disease biology and drug effects. The group also has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response. Prior to returning to academia in 2004, Dr. Carr held scientific leadership positions at GlaxoSmithKline where he was the director of computational and structural sciences and at Millennium Pharmaceuticals where he was senior director of protein science and technology. Dr. Carr has more than 280 publications on the development and use of proteomics and biological mass spectrometry. He is deputy editor of Molecular and Cellular Proteomics, the leading journal in the field of proteomics. Dr. Carr received his B.S. from Union College and Ph.D. from MIT.

Barry Karger, PhD

Barry Karger is a Co-founder of BioAnalytix and is the Emeritus James L. Waters Chair in Analytical Chemistry and Distinguished Professor. He was the Founding Director of the Barnett Institute of Chemical and Biological Analysis at Northeastern University and was its director for over 40 years. Dr. Karger has been an active researcher with 375 publications and 50 patents in the field of bioanalytical chemistry, with particular emphasis in liquid chromatography, capillary electrophoresis and mass spectrometry. More than 200 Ph.Ds and post doctoral students worked under his direction. For his many contributions to Northeastern University, a medal was established in his name, awarded biannually, to a scientist with outstanding contributions in the field of bioanalytical chemistry. Dr. Karger has received many honors including three American Chemical Society awards, the prestigious Bergman Medal from the Swedish Chemical Society, and the Herovsky Gold Medal from the Czech Academy of Sciences, and the Beckman Medal for major contributions to electrophoretic separations. Dr. Karger has been a major contributor to the development of HPLC, and his technology in capillary electrophoresis played a significant role in the Human Genome Project. More recently he has been involved in the development of new technologies for proteomics, especially trace level LC/MS analysis of proteins in biological matrices, and comprehensive characterization of complex protein structures. He has actively collaborated with a number of companies in the biotechnology industry, especially in the characterization of biopharmaceuticals and the biology of production cell lines.

Kathryn Stein, PhD

Kathryn Stein is an immunologist with over 30 years of experience in biotechnology as a senior manager at the FDA and as an executive in industry. She is an expert in the field of polysaccharide-protein conjugate vaccines and monoclonal antibodies. During her 22 years at the FDA, the last 10 as the first Director of the Division of Monoclonal Antibodies, Dr. Stein was a leader in developing policies to regulate polysaccharide-protein conjugate vaccines, monoclonal antibodies and other recombinant DNA-derived products. She was lead or co-author on all of the guidance documents published by the FDA with respect to monoclonal antibodies and a co-author of the FDA guidance on comparability. Dr. Stein was one of the approving officials for the Haemophilus influenza type b (Hib) vaccines for routine use in infants. She was a member of the review committee of the first approved monoclonal antibody, OKT3™, and one of the approving officials for the subsequent 15 monoclonal antibodies approved through the first half of 2002, including abciximab, rituximab, palivizumab, trastuzumab, infliximab, and alemtuzumab. Dr. Stein received numerous awards for her review and policy work at the FDA. She was the 2014 recipient of the John and Samuel Bard Award in Medicine and Science from Bard College, Annandale-on-Hudson, NY. In 2002, Dr. Stein left the FDA to join MacroGenics where she was responsible for establishing the Product Development and Regulatory Affairs, Project Management, Quality and Manufacturing departments. She served as Senior Vice President, Product Development and Regulatory Affairs until 2016. Under Dr. Stein’s leadership during her 14 year tenure, MacroGenics brought eight products into the clinic, seven of them newly developed by MacroGenics and one in-licensed as a phase 2/3 asset. Dr. Stein received a BA in chemistry from Bard College and a PhD in microbiology and immunology from the Sue Golding Graduate Division of the Albert Einstein College of Medicine. Prior to joining the FDA, she was a post-doctoral Fellow at Harvard with Dr. Harvey Cantor and at NIH with Dr. William Paul. At FDA she was a Staff Fellow, Senior Investigator, and the first Director of the Division of Monoclonal Antibodies, Office of Therapeutics Research and Review, CBER, FDA. She maintained a research laboratory for her entire 22 year career at FDA and was a leading investigator in polysaccharide-protein conjugate vaccines. She has over 60 peer-reviewed publications.

Ralph Weissleder, MD, PhD

Ralph Weissleder is a Professor at Harvard Medical School, Director of the Center for Systems Biology at Massachusetts General Hospital (MGH), and Attending Clinician (Interventional Radiology) at MGH. Dr. Weissleder is also a member of the Department of Systems Biology at HMS and the Dana Farber Harvard Cancer Center. Dr. Weissleder’s research interests include the development of novel molecular imaging techniques, tools for detection of early disease detection, development of nanomaterials for sensing and systems analysis. His research has been translational and several of his developments have been licensed to companies and led to advanced clinical trials with anticipated major impacts when these methods become routinely available. He has published over 850 publications in peer reviewed journals (H-index greater than 160) and has authored several textbooks. He is a founding member of the Society for Molecular Imaging Research and has served as its President in 2002. He is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the National Academy of Inventors and the German Academy of Sciences (Leopoldina). His work has been honored with numerous awards including the J. Taylor International Prize in Medicine, the Millenium Pharmaceuticals Innovator Award, the AUR Memorial Award, the ARRS President's Award, The Society for Molecular Imaging Lifetime Achievement Award, the Academy of Molecular Imaging 2006 Distinguished Basic Scientist Award and the 2008 RSNA Outstanding Researcher Award.

John R. Yates, PhD

John R. Yates is the Ernest W. Hahn Professor in the Departments of Molecular Medicine and Neurobiology at The Scripps Research Institute. His research interests include development of integrated methods for tandem mass spectrometry analysis of protein mixtures, bioinformatics using mass spectrometry data, and biological studies involving proteomics. He is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database and developer of the shotgun proteomics technique for the analysis of protein mixtures. His laboratory has developed the use of proteomic techniques to analyze protein complexes, posttranslational modifications, organelles and quantitative analysis of protein expression for the discovery of new biology. Many proteomic approaches developed by Dr. Yates have become a national and international resource to many investigators in the scientific community. He has received the American Society for Mass Spectrometry research award, the Pehr Edman Award in Protein Chemistry, the American Society for Mass Spectrometry Biemann Medal, the HUPO Distinguished Achievement Award in Proteomics, Herbert Sober Award from the ASBMB, and the Christian Anfinsen Award from The Protein Society, the 2015 ACS’s Analytical Chemistry award and 2015 The Ralph N. Adams Award in Bioanalytical Chemistry. He was ranked by Citation Impact, Science Watch as one of the Top 100 Chemists for the decade, 2000-2010. He was #1 on a List of Most Influential in Analytical Chemistry compiled by The Analytical Scientist 10/30/2013 and is on the List Of Most Highly Influential Biomedical Researchers, 1996-2011, European J. Clinical Investigation 2013, 43, 1339-1365 and the Thomson Reuters 2015 List of Highly Cited Scientists. He has published over 900 scientific articles with ~106,000 citations, and an H index greater than 163 (Google Scholar). Dr. Yates is the Editor in Chief at the Journal of Proteome Research.

Back to top